Document is current
Any future updates will be listed below
-
Authors
Arffman, Maare https://orcid.org/0009-0004-1837-1587
Meriranta, Leo
Jørgensen, Judit
Karjalainen-Lindsberg, Marja-Liisa
Beiske, Klaus
Pedersen, Mette
Drott, Kristina
Fluge, Øystein
Jyrkkiö, Sirkku
Brown, Peter https://orcid.org/0000-0002-6522-4086
Holte, Harald https://orcid.org/0000-0001-9799-9428
Leppä, Sirpa https://orcid.org/0000-0002-8265-511X
-
Funding
Funding for this research was provided by:
Academy of Finland
Sigrid Juséliuksen Säätiö
Helsingin ja Uudenmaan Sairaanhoitopiiri
Helsingin Yliopisto
Syöpäsäätiö
iCAN Digital Precision Cancer Medicine Flagship
Orionin Tutkimussäätiö
Ida Montinin Säätiö
Biomedicum Helsinki-säätiö
- License Information
-
More Information
Article History
Received: 13 November 2025
Revised: 3 March 2026
Accepted: 27 March 2026
First Online: 22 April 2026
Competing interests
: J.J*: AbbVie: Consultancy; BMS: Consultancy; Caribou Bioscience: Consultancy; Gilead: Consultancy; Incyte: Consultancy; Novartis: Consultancy; Roche: Consultancy. Sobi: Consultancy. K.D*: AbbVie: Honoraria, Roche: Honoraria, Respiratorius: Honoraria, Incyte: Advisory board. P.B*: BMS: Consultancy; Roche: Consultancy, Novartis: Consultancy H.H*: Genmab: Safety Committee; Incyte: Consultancy; Novartis: Research Funding; Elicera Therapeutics: Safety Committee; Serb SA: Advisory Board S.L*: AbbVie: Honoraria, Consultation; AstraZeneca: Consultation; GENMAB: Research Funding**;GILEAD: Honoraria; Incyte, Consultation, Honoraria; Novartis: Research Funding*; Roche: Honoraria, Consultancy, Research Funding*; BMS/Celgene: Consultancy, Research Funding**. Other authors declare no conflicts of interest. *All outside of the submitted work. **To the institute.
: Part of the work has been presented at the AACR Annual Meeting 2025.
